{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:02:10Z","timestamp":1779811330888,"version":"3.53.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01251-w","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:18:10Z","timestamp":1778084290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Utility and Constraints of the Competitive Counter Flow (CCF) Assay in OATP1B1 Substrate Profiling"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1460-1274","authenticated-orcid":false,"given":"Sumathy","family":"Mathialagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-5488","authenticated-orcid":false,"given":"Mark A.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5064-2006","authenticated-orcid":false,"given":"Emi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4299-4203","authenticated-orcid":false,"given":"Hannah M.","family":"Moulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9316-6841","authenticated-orcid":false,"given":"Brendon","family":"Kapinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4179-2377","authenticated-orcid":false,"given":"Sasan","family":"Paryad Zanjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5843-7959","authenticated-orcid":false,"given":"David A.","family":"Tess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1284-2769","authenticated-orcid":false,"given":"Emi","family":"Kimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-6329","authenticated-orcid":false,"given":"Manthena V. S.","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8121-8746","authenticated-orcid":false,"given":"Sook Wah","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"2","key":"1251_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmr.2024.100023","volume":"77","author":"B Hagenbuch","year":"2025","unstructured":"Hagenbuch B, Stieger B, Locher KP. Organic anion transporting polypeptides: pharmacology, toxicology, structure, and transport mechanisms. Pharmacol Rev. 2025;77(2):100023.","journal-title":"Pharmacol Rev"},{"issue":"4","key":"1251_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/cts.12623","volume":"12","author":"SJ McFeely","year":"2019","unstructured":"McFeely SJ, Ritchie TK, Yu J, Nordmark A, Levy RH, Ragueneau-Majlessi I. Identification and evaluation of clinical substrates of organic anion transporting polypeptides 1B1 and 1B3. Clin Transl Sci. 2019;12(4):379\u201387.","journal-title":"Clin Transl Sci"},{"issue":"3","key":"1251_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/cpt.2671","volume":"112","author":"X Yang","year":"2022","unstructured":"Yang X, Reynolds K, Madabushi R, Huang SM. Current perspective on residual knowledge gaps in the assessment of transporter-mediated drug interactions. Clin Pharmacol Ther. 2022;112(3):450\u20132.","journal-title":"Clin Pharmacol Ther"},{"key":"1251_CR4","unstructured":"International council for the harmonization of technical documents \u2013 ICH M12 guideline for drug interaction studies."},{"issue":"3","key":"1251_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/cpt.2678","volume":"112","author":"MVS Varma","year":"2022","unstructured":"Varma MVS. Clinical relevance of organic anion transporting polypeptide 1B-mediated hepatic uptake for high-permeability drugs: a perspective. Clin Pharmacol Ther. 2022;112(3):446\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1251_CR6","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1007\/s11095-015-1749-4","volume":"32","author":"MV Varma","year":"2015","unstructured":"Varma MV, Steyn SJ, Allerton C, El-Kattan AF. Predicting clearance mechanism in drug discovery: Extended Clearance Classification System (ECCS). Pharm Res. 2015;32(12):3785\u2013802.","journal-title":"Pharm Res"},{"issue":"1","key":"1251_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1124\/jpet.120.000457","volume":"377","author":"H Eng","year":"2021","unstructured":"Eng H, Bi YA, West MA, Ryu S, Yamaguchi E, Kosa RE, et al. Organic Anion-Transporting Polypeptide 1B1\/1B3-mediated hepatic uptake determines the pharmacokinetics of large lipophilic acids: in vitro-in vivo evaluation in Cynomolgus monkey. J Pharmacol Exp Ther. 2021;377(1):169\u201380.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1251_CR8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/cpt.520","volume":"101","author":"MV Varma","year":"2017","unstructured":"Varma MV, Kimoto E, Scialis R, Bi Y, Lin J, Eng H, et al. Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast. Clin Pharmacol Ther. 2017;101(3):406\u201315.","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"1251_CR9","doi-asserted-by":"publisher","first-page":"7358","DOI":"10.1021\/acs.jmedchem.8b01007","volume":"61","author":"HC Chien","year":"2018","unstructured":"Chien HC, Colas C, Finke K, Springer S, Stoner L, Zur AA, et al. Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1). J Med Chem. 2018;61(16):7358\u201373.","journal-title":"J Med Chem"},{"key":"1251_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312926","author":"CR Lefevre","year":"2021","unstructured":"Lefevre CR, Le Vee M, Gaubert S, Jouan E, Bruyere A, Moreau C, et al. Substrate-dependent trans-stimulation of Organic Cation Transporter 2 activity. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222312926.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1251_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1124\/dmd.117.076554","volume":"46","author":"WEA Ellawatty","year":"2018","unstructured":"Ellawatty WEA, Masuo Y, Fujita KI, Yamazaki E, Ishida H, Arakawa H, et al. Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor Pazopanib. Drug Metab Dispos. 2018;46(1):33\u201340.","journal-title":"Drug Metab Dispos"},{"key":"1251_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.969363","volume":"13","author":"RD Schnegelberger","year":"2022","unstructured":"Schnegelberger RD, Steiert B, Sandoval PJ, Hagenbuch B. Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3. Front Physiol. 2022;13:969363.","journal-title":"Front Physiol"},{"issue":"9","key":"1251_CR13","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1158\/2767-9764.CRC-24-0332","volume":"4","author":"T Drabison","year":"2024","unstructured":"Drabison T, Boeckman M, Yang Y, Huang KM, de Bruijn P, Nepal MR, et al. Systematic evaluation of tyrosine kinase inhibitors as OATP1B1 substrates using a competitive counterflow screen. Cancer Res Commun. 2024;4(9):2489\u201397.","journal-title":"Cancer Res Commun"},{"issue":"5","key":"1251_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s13318-024-00902-7","volume":"49","author":"O Fardel","year":"2024","unstructured":"Fardel O, Moreau A, Carteret J, Denizot C, Le Vee M, Parmentier Y. The competitive counterflow assay for identifying drugs transported by solute carriers: principle, applications, challenges\/limits, and perspectives. Eur J Drug Metab Pharmacokinet. 2024;49(5):527\u201339.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"12","key":"1251_CR15","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1021\/acs.molpharmaceut.8b00631","volume":"15","author":"AM Schafer","year":"2018","unstructured":"Schafer AM, Bock T, Meyer Zu Schwabedissen HE. Establishment and validation of competitive counterflow as a method to detect substrates of the Organic Anion Transporting Polypeptide 2B1. Mol Pharm. 2018;15(12):5501\u201313.","journal-title":"Mol Pharm"},{"issue":"3","key":"1251_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1124\/mol.118.114066","volume":"95","author":"AM Schafer","year":"2019","unstructured":"Schafer AM, Potterat O, Seibert I, Fertig O, Meyer Zu Schwabedissen HE. Hyperforin-induced activation of the Pregnane X Receptor is influenced by the Organic Anion-Transporting Polypeptide 2B1. Mol Pharmacol. 2019;95(3):313\u201323.","journal-title":"Mol Pharmacol"},{"issue":"11","key":"1251_CR17","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202300530RR","volume":"37","author":"O Ungvari","year":"2023","unstructured":"Ungvari O, Bakos E, Kovacsics D, Ozvegy-Laczka C. The fluorescence-based competitive counterflow assay developed for organic anion transporting polypeptides 1A2, 1B1, 1B3 and 2B1 identifies pentamidine as a selective OATP1A2 substrate. FASEB J. 2023;37(11):e23223.","journal-title":"FASEB J"},{"issue":"1","key":"1251_CR18","doi-asserted-by":"publisher","first-page":"F56","DOI":"10.1152\/ajprenal.00486.2012","volume":"304","author":"JN Harper","year":"2013","unstructured":"Harper JN, Wright SH. Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2. Am J Physiol Renal Physiol. 2013;304(1):F56-67.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1251_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.bcp.2018.08.028","volume":"156","author":"KH Boxberger","year":"2018","unstructured":"Boxberger KH, Hagenbuch B, Lampe JN. Ligand-dependent modulation of hOCT1 transport reveals discrete ligand binding sites within the substrate translocation channel. Biochem Pharmacol. 2018;156:371\u201384.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"1251_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1124\/jpet.117.241406","volume":"362","author":"BC Burckhardt","year":"2017","unstructured":"Burckhardt BC, Henjakovic M, Hagos Y, Burckhardt G. Differential interaction of Dantrolene, Glafenine, Nalidixic Acid, and Prazosin with human organic anion transporters 1 and 3. J Pharmacol Exp Ther. 2017;362(3):450\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1251_CR21","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1124\/mol.117.111161","volume":"94","author":"HE Meyer Zu Schwabedissen","year":"2018","unstructured":"Meyer Zu Schwabedissen HE, Ferreira C, Schaefer AM, Oufir M, Seibert I, Hamburger M, et al. Thyroid hormones are transport substrates and transcriptional regulators of organic anion transporting polypeptide 2B1. Mol Pharmacol. 2018;94(1):700\u201312.","journal-title":"Mol Pharmacol"},{"issue":"2","key":"1251_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1055\/a-1305-3936","volume":"88","author":"AM Schafer","year":"2022","unstructured":"Schafer AM, Gilgen PM, Spirgi C, Potterat O, Meyer Zu Schwabedissen HE. Constituents of Passiflora incarnata, but not of Valeriana officinalis, interact with the organic anion transporting polypeptides (OATP)2B1 and OATP1A2. Planta Med. 2022;88(2):152\u201362.","journal-title":"Planta Med"},{"key":"1251_CR23","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.123.001630","author":"YA Bi","year":"2024","unstructured":"Bi YA, Jordan S, King-Ahmad A, West MA, Yamaguchi E, Ryu S, et al. Low molecular weight acids and OATP1B mediated hepatic clearance: in vitro and in vivo evaluation using novel hypoxia-inducible factor prolyl hydroxylase inhibitors (Dustats). Drug Metab Dispos. 2024. https:\/\/doi.org\/10.1124\/dmd.123.001630.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1251_CR24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/cpt.2434","volume":"111","author":"E Kimoto","year":"2022","unstructured":"Kimoto E, Costales C, West MA, Bi YA, Vourvahis M, David Rodrigues A, et al. Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions. Clin Pharmacol Ther. 2022;111(2):404\u201315.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1251_CR25","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1124\/jpet.118.252049","volume":"367","author":"E Kimoto","year":"2018","unstructured":"Kimoto E, Mathialagan S, Tylaska L, Niosi M, Lin J, Carlo AA, et al. Organic anion transporter 2-mediated hepatic uptake contributes to the clearance of high-permeability-low-molecular-weight acid and zwitterion drugs: Evaluation using 25 drugs. J Pharmacol Exp Ther. 2018;367(2):322\u201334.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"1251_CR26","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1021\/jm300212s","volume":"55","author":"M Karlgren","year":"2012","unstructured":"Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, et al. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012;55(10):4740\u201363.","journal-title":"J Med Chem"},{"issue":"1","key":"1251_CR27","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ejps.2012.04.003","volume":"47","author":"P Sharma","year":"2012","unstructured":"Sharma P, Butters CJ, Smith V, Elsby R, Surry D. Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. Eur J Pharm Sci. 2012;47(1):244\u201355.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"1251_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1124\/jpet.119.257600","volume":"370","author":"YA Bi","year":"2019","unstructured":"Bi YA, Costales C, Mathialagan S, West M, Eatemadpour S, Lazzaro S, et al. Quantitative contribution of six major transporters to the hepatic uptake of drugs: \u201cSLC-phenotyping\u201d using primary human hepatocytes. J Pharmacol Exp Ther. 2019;370(1):72\u201383.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1251_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1208\/s12248-017-0051-2","volume":"19","author":"YA Bi","year":"2017","unstructured":"Bi YA, Scialis RJ, Lazzaro S, Mathialagan S, Kimoto E, Keefer J, et al. Reliable rate measurements for active and passive hepatic uptake using plated human hepatocytes. AAPS J. 2017;19(3):787\u201396.","journal-title":"AAPS J"},{"issue":"3","key":"1251_CR30","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1021\/acs.molpharmaceut.7b01108","volume":"15","author":"YA Bi","year":"2018","unstructured":"Bi YA, Lin J, Mathialagan S, Tylaska L, Callegari E, Rodrigues AD, et al. Role of hepatic organic anion transporter 2 in the pharmacokinetics of R- and S-Warfarin: in vitro studies and mechanistic evaluation. Mol Pharm. 2018;15(3):1284\u201395.","journal-title":"Mol Pharm"},{"issue":"5","key":"1251_CR31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40262-014-0222-6","volume":"54","author":"BJ Brennan","year":"2015","unstructured":"Brennan BJ, Poirier A, Moreira S, Morcos PN, Goelzer P, Portmann R, et al. Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir. Clin Pharmacokinet. 2015;54(5):537\u201349.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1251_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1124\/dmd.119.088948","volume":"48","author":"CM Bowman","year":"2020","unstructured":"Bowman CM, Chen E, Chen L, Chen YC, Liang X, Wright M, et al. Changes in organic anion transporting polypeptide uptake in HEK293 overexpressing cells in the presence and absence of human plasma. Drug Metab Dispos. 2020;48(1):18\u201324.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1251_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1124\/jpet.104.068056","volume":"311","author":"M Hirano","year":"2004","unstructured":"Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004;311(1):139\u201346.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1251_CR34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1124\/jpet.114.215970","volume":"351","author":"MV Varma","year":"2014","unstructured":"Varma MV, Bi YA, Kimoto E, Lin J. Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1B1 substrates using a mechanistic net-effect model. J Pharmacol Exp Ther. 2014;351(1):214\u201323.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1251_CR35","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1021\/acs.molpharmaceut.3c00934","volume":"21","author":"W Han","year":"2024","unstructured":"Han W, Bo Z, Liang T, Liu H, Li L, Guo Z. G45 and V386 in transmembrane domains 1 and 8 are critical for the activation of OATP1B3-mediated E17betaG uptake by clotrimazole. Mol Pharm. 2024;21(2):854\u201363.","journal-title":"Mol Pharm"},{"key":"1251_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2019.114642","volume":"378","author":"X Wang","year":"2019","unstructured":"Wang X, Chen J, Xu S, Ni C, Fang Z, Hong M. Amino-terminal region of human organic anion transporting polypeptide 1B1 dictates transporter stability and substrate interaction. Toxicol Appl Pharmacol. 2019;378:114642.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1251_CR37","doi-asserted-by":"crossref","unstructured":"Parvez MM, Kaisar N, Shin HJ, Lee YJ, Shin JG. Erratum for Parvez et al., \"Comprehensive Substrate Characterization of 22 Antituberculosis Drugs for Multiple Solute Carrier (SLC) Uptake Transporters In Vitro\". Antimicrob Agents Chemother. 2019;63(1).","DOI":"10.1128\/AAC.02311-18"},{"issue":"5","key":"1251_CR38","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2133\/dmpk.23.347","volume":"23","author":"M Nakakariya","year":"2008","unstructured":"Nakakariya M, Shimada T, Irokawa M, Maeda T, Tamai I. Identification and species similarity of OATP transporters responsible for hepatic uptake of beta-lactam antibiotics. Drug Metab Pharmacokinet. 2008;23(5):347\u201355.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"12","key":"1251_CR39","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1021\/acs.molpharmaceut.5b00453","volume":"12","author":"S Durmus","year":"2015","unstructured":"Durmus S, Lozano-Mena G, van Esch A, Wagenaar E, van Tellingen O, Schinkel AH. Preclinical mouse models to study human OATP1B1- and OATP1B3-mediated drug-drug interactions in vivo. Mol Pharm. 2015;12(12):4259\u201369.","journal-title":"Mol Pharm"},{"issue":"7","key":"1251_CR40","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1124\/dmd.105.009175","volume":"34","author":"N Ishiguro","year":"2006","unstructured":"Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an Angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006;34(7):1109\u201315.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1251_CR41","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1021\/acs.molpharmaceut.8b00138","volume":"15","author":"S Izumi","year":"2018","unstructured":"Izumi S, Nozaki Y, Kusuhara H, Hotta K, Mochizuki T, Komori T, et al. Relative Activity Factor (RAF)-Based Scaling of Uptake Clearance Mediated by Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 in Human Hepatocytes. Mol Pharm. 2018;15(6):2277\u201388.","journal-title":"Mol Pharm"},{"issue":"7","key":"1251_CR42","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/psp4.13154","volume":"13","author":"T Tsuchitani","year":"2024","unstructured":"Tsuchitani T, Tomaru A, Aoki Y, Ishiguro N, Tsuda Y, Sugiyama Y. Elucidating nonlinear pharmacokinetics of telmisartan: integration of target-mediated drug disposition and OATP1B3-mediated hepatic uptake in a physiologically based model. CPT Pharmacomet Syst Pharmacol. 2024;13(7):1224\u201337.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"4","key":"1251_CR43","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s11095-006-9196-x","volume":"24","author":"Y Uwai","year":"2007","unstructured":"Uwai Y, Ida H, Tsuji Y, Katsura T, Inui K. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res. 2007;24(4):811\u20135.","journal-title":"Pharm Res"},{"issue":"1","key":"1251_CR44","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1124\/mol.117.111153","volume":"94","author":"L Zou","year":"2018","unstructured":"Zou L, Stecula A, Gupta A, Prasad B, Chien HC, Yee SW, et al. Molecular mechanisms for species differences in Organic Anion Transporter 1, OAT1: implications for renal drug toxicity. Mol Pharmacol. 2018;94(1):689\u201399.","journal-title":"Mol Pharmacol"},{"issue":"12","key":"1251_CR45","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1016\/j.xphs.2019.08.012","volume":"108","author":"H Murata","year":"2019","unstructured":"Murata H, Ito S, Kusuhara H, Nomura Y, Taniguchi T. Proposal of a parameter for OATP1B1 inhibition screening at the early drug discovery stage. J Pharm Sci. 2019;108(12):3898\u2013902.","journal-title":"J Pharm Sci"},{"issue":"Suppl 7","key":"1251_CR46","first-page":"S59","volume":"56","author":"J Vaidyanathan","year":"2016","unstructured":"Vaidyanathan J, Yoshida K, Arya V, Zhang L. Comparing various in vitro prediction criteria to assess the potential of a new molecular entity to inhibit Organic Anion Transporting Polypeptide 1B1. J Clin Pharmacol. 2016;56(Suppl 7):S59-72.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"1251_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmd.2025.100101","volume":"53","author":"Y Li","year":"2025","unstructured":"Li Y, Yabut J, Zhang Z, Fauty S, Houle R, Miller H, et al. Characterization of organic anion transporting polypeptide (OATP)1B1 and OATP1B3 humanized rat as a translational model to study the pharmacokinetics of OATP1B substrate drugs. Drug Metab Dispos. 2025;53(7):100101.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"1251_CR48","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s11095-018-2511-5","volume":"35","author":"SJ Rhee","year":"2018","unstructured":"Rhee SJ, Lee HA, Lee S, Kim E, Jeon I, Song IS, et al. Physiologically based pharmacokinetic modeling of fimasartan, amlodipine, and hydrochlorothiazide for the investigation of drug-drug interaction potentials. Pharm Res. 2018;35(12):236.","journal-title":"Pharm Res"},{"issue":"5","key":"1251_CR49","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/FJC.0b013e31822b9092","volume":"58","author":"KH Shin","year":"2011","unstructured":"Shin KH, Kim TE, Kim SE, Lee MG, Song IS, Yoon SH, et al. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. J Cardiovasc Pharmacol. 2011;58(5):492\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"1251_CR50","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/FJC.0b013e31821795d0","volume":"57","author":"S Yi","year":"2011","unstructured":"Yi S, Kim TE, Yoon SH, Cho JY, Shin SG, Jang IJ, et al. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol. 2011;57(6):682\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"1251_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41552-8","volume":"14","author":"AD Ciuta","year":"2023","unstructured":"Ciuta AD, Nosol K, Kowal J, Mukherjee S, Ramirez AS, Stieger B, et al. Structure of human drug transporters OATP1B1 and OATP1B3. Nat Commun. 2023;14(1):5774.","journal-title":"Nat Commun"},{"issue":"15","key":"1251_CR52","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1158\/1078-0432.CCR-21-0023","volume":"27","author":"ER Hayden","year":"2021","unstructured":"Hayden ER, Chen M, Pasquariello KZ, Gibson AA, Petti JJ, Shen S, et al. Regulation of OATP1B1 function by tyrosine kinase-mediated phosphorylation. Clin Cancer Res. 2021;27(15):4301\u201310.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1251_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmd.2025.100138","volume":"53","author":"V Xu","year":"2025","unstructured":"Xu V, Nepal MR, Ahmed E, Kaczynski BD, Xu Y, Gallo JM, et al. Regulation of hepatic organic anion transporting polypeptide 1B-type transport function by the protein kinase LYN. Drug Metab Dispos. 2025;53(9):100138.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1251_CR54","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/jps.24564","volume":"105","author":"T De Bruyn","year":"2016","unstructured":"De Bruyn T, Stieger B, Augustijns PF, Annaert PP. Clearance prediction of HIV protease inhibitors in man: role of hepatic uptake. J Pharm Sci. 2016;105(2):854\u201363.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1251_CR55","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1124\/dmd.114.059105","volume":"43","author":"S Izumi","year":"2015","unstructured":"Izumi S, Nozaki Y, Maeda K, Komori T, Takenaka O, Kusuhara H, et al. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions. Drug Metab Dispos. 2015;43(2):235\u201347.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1251_CR56","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1124\/dmd.113.054767","volume":"42","author":"K Takeuchi","year":"2014","unstructured":"Takeuchi K, Sugiura T, Matsubara K, Sato R, Shimizu T, Masuo Y, et al. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans. Drug Metab Dispos. 2014;42(4):726\u201334.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1251_CR57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/0091270011433328","volume":"53","author":"JW Kim","year":"2013","unstructured":"Kim JW, Yi S, Kim TE, Lim KS, Yoon SH, Cho JY, et al. Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. J Clin Pharmacol. 2013;53(1):75\u201381.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1251_CR58","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s11095-012-0956-5","volume":"30","author":"MV Varma","year":"2013","unstructured":"Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, Kumar V. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm Res. 2013;30(4):1188\u201399.","journal-title":"Pharm Res"},{"issue":"3","key":"1251_CR59","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1515\/dmdi-2013-0062","volume":"29","author":"V Khurana","year":"2014","unstructured":"Khurana V, Minocha M, Pal D, Mitra AK. Role of OATP-1B1 and\/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. Drug Metabol Drug Interact. 2014;29(3):179\u201390.","journal-title":"Drug Metabol Drug Interact"},{"issue":"6","key":"1251_CR60","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1158\/1078-0432.CCR-12-3306","volume":"19","author":"EI Zimmerman","year":"2013","unstructured":"Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, et al. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013;19(6):1458\u201366.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1251_CR61","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.xphs.2020.10.016","volume":"110","author":"JE Park","year":"2021","unstructured":"Park JE, Shitara Y, Lee W, Morita S, Sahi J, Toshimoto K, et al. Improved prediction of the drug-drug interactions of pemafibrate caused by Cyclosporine A and rifampicin via PBPK modeling: consideration of the albumin-mediated hepatic uptake of pemafibrate and inhibition constants with preincubation against OATP1B. J Pharm Sci. 2021;110(1):517\u201328.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1251_CR62","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1124\/mol.108.046458","volume":"74","author":"H Zaher","year":"2008","unstructured":"Zaher H, Meyer zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, et al. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2\/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol. 2008;74(2):320\u20139.","journal-title":"Mol Pharmacol"},{"issue":"8","key":"1251_CR63","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s11095-017-2168-5","volume":"34","author":"T Yoshikado","year":"2017","unstructured":"Yoshikado T, Maeda K, Furihata S, Terashima H, Nakayama T, Ishigame K, et al. A clinical cassette dosing study for evaluating the contribution of hepatic OATPs and CYP3A to drug-drug interactions. Pharm Res. 2017;34(8):1570\u201383.","journal-title":"Pharm Res"},{"issue":"5","key":"1251_CR64","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/clpt.2012.106","volume":"92","author":"CS Lancaster","year":"2012","unstructured":"Lancaster CS, Bruun GH, Peer CJ, Mikkelsen TS, Corydon TJ, Gibson AA, et al. OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther. 2012;92(5):642\u201350.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1251_CR65","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/bcpt.12992","volume":"123","author":"Y Chen","year":"2018","unstructured":"Chen Y, Chen L, Zhang H, Huang S, Xiong Y, Xia C. Interaction of sulfonylureas with liver uptake transporters OATP1B1 and OATP1B3. Basic Clin Pharmacol Toxicol. 2018;123(2):147\u201354.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1251_CR66","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00512-18","author":"MM Parvez","year":"2018","unstructured":"Parvez MM, Kaisar N, Shin HJ, Lee YJ, Shin JG. Comprehensive substrate characterization of 22 antituberculosis drugs for multiple solute carrier (SLC) uptake transporters in vitro. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.00512-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1251_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00802","volume":"11","author":"Y Ni","year":"2020","unstructured":"Ni Y, Duan Z, Zhou D, Liu S, Wan H, Gui C, et al. Identification of structural features for the inhibition of OAT3-mediated uptake of enalaprilat by selected drugs and flavonoids. Front Pharmacol. 2020;11:802.","journal-title":"Front Pharmacol"},{"issue":"12","key":"1251_CR68","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.2337\/dc21-1152","volume":"44","author":"AY Dawed","year":"2021","unstructured":"Dawed AY, Yee SW, Zhou K, van Leeuwen N, Zhang Y, Siddiqui MK, et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care. 2021;44(12):2673\u201382.","journal-title":"Diabetes Care"},{"issue":"11","key":"1251_CR69","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1124\/dmd.114.058784","volume":"42","author":"JW Higgins","year":"2014","unstructured":"Higgins JW, Ke AB, Zamek-Gliszczynski MJ. Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1. Drug Metab Dispos. 2014;42(11):1780\u20134.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1251_CR70","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1124\/dmd.107.018374","volume":"36","author":"JW Polli","year":"2008","unstructured":"Polli JW, Humphreys JE, Harmon KA, Castellino S, O\u2019Mara MJ, Olson KL, et al. The role of efflux and uptake transporters in [N-3-chloro-4-[(3-fluorobenzyl)oxy]phenyl-6-[5-([2-(methylsulfonyl)ethyl]aminomethyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008;36(4):695\u2013701.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1251_CR71","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1208\/s12248-016-9871-8","volume":"18","author":"TT Nieskens","year":"2016","unstructured":"Nieskens TT, Peters JG, Schreurs MJ, Smits N, Woestenenk R, Jansen K, et al. A human renal proximal tubule cell line with stable organic anion transporter 1 and 3 expression predictive for antiviral-induced toxicity. AAPS J. 2016;18(2):465\u201375.","journal-title":"AAPS J"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01251-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01251-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01251-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:02:29Z","timestamp":1779807749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01251-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":71,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["1251"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01251-w","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"18 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors were full-time employees of Pfizer Inc at the time of this study. The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Copilot is used only for AI assisted copy editing.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"A.I. Disclosure"}}],"article-number":"101"}}